Who are Viking Therapeutics, Inc.'s main suppliers?

Viking Therapeutics, Inc. (VKTX) key suppliers include: Ligand Pharmaceuticals Incorporated, ONE-PACIFIC-HEIGHTS-LLC, Ligand Pharmaceuticals Incorporated, Alnylam Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc. and 22 more. View the full supplier network at chainsifter.com/chain/VKTX.

Who are Viking Therapeutics, Inc.'s major customers?

Viking Therapeutics, Inc. (VKTX) key customers include: Corbus Pharmaceuticals Holdings, Inc., iBio, Inc., Ligand Pharmaceuticals Incorporated, Ligand Pharmaceuticals Incorporated, LGNZZ and 8 more. View the full customer network at chainsifter.com/chain/VKTX.

What sector is Viking Therapeutics, Inc. in?

Viking Therapeutics, Inc. (VKTX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Viking Therapeutics, Inc. Suppliers, Customers & Supply Chain (VKTX)

27Suppliers

13Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Viking Therapeutics, Inc. (VKTX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

43Total relationships

4Distinct source URLs

6High confidence

0.737Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Viking Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
LGND	Ligand Pharmaceuticals Incorporated	92%	Reciprocal relationship from LGND graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from LGND graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from LGND g…
ONE-PACIFIC-HEIGHTS-LLC	ONE-PACIFIC-HEIGHTS-LLC	92%	In November 2021, the Company entered into an Office Lease (the “Office Lease”) with One Pacific Heights. LLC.
LGND	Ligand Pharmaceuticals Incorporated	90%	from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therapies that are in various stages of clinical development for conditions characterized…
ALNY	Alnylam Pharmaceuticals, Inc.	72%	y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products …
ALNY	Alnylam Pharmaceuticals, Inc.	72%	Reciprocal relationship from ALNY graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from ALNY g…
ARWR	Arrowhead Pharmaceuticals, Inc.	72%	y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products …
ARWR	Arrowhead Pharmaceuticals, Inc.	72%	Reciprocal relationship from ARWR graph: Reciprocal relationship from VKTX graph: y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with …
BHC	Bausch Health Companies Inc.	72%	y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products …
BHC	Bausch Health Companies Inc.	72%	Reciprocal relationship from BHC graph: Reciprocal relationship from VKTX graph: y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with G…
CRBP	Corbus Pharmaceuticals Holdings, Inc.	72%	Reciprocal relationship from CRBP graph: designed to be an improved next-generation site-specific Nectin-4 targeting antibody drug conjugate. CRB-701 is a monoclonal antibody attached to an MMAE cyto…
GLMD	Galmed Pharmaceuticals Ltd.	72%	y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products …
GLMD	Galmed Pharmaceuticals Ltd.	72%	Reciprocal relationship from GLMD graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from GLMD graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from GLMD g…
GPCR	Structure Therapeutics Inc.	72%	y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products …
GPCR	Structure Therapeutics Inc.	72%	Reciprocal relationship from GPCR graph: Reciprocal relationship from VKTX graph: y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with …
GYRE	Gyre Therapeutics, Inc.	72%	Reciprocal relationship from GYRE graph: associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidates F573 is our clinical-stage product can…
HEPA	Hepion Pharmaceuticals, Inc.	72%	Reciprocal relationship from HEPA graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from HEPA graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from HEPA g…
HEPA	Hepion Pharmaceuticals, Inc.	72%	y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products …
IBIO	iBio, Inc.	72%	Reciprocal relationship from IBIO graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from IBIO g…
LGNZZ	LGNZZ	72%	from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therapies that are in various stages of clinical development for conditions characterized…
LGNZZ	LGNZZ	72%	Reciprocal relationship from LGNZZ graph: Reciprocal relationship from VKTX graph: from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therap…
MDGL	Madrigal Pharmaceuticals, Inc.	72%	y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products …
MDGL	Madrigal Pharmaceuticals, Inc.	72%	Reciprocal relationship from MDGL graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from MDGL graph: Reciprocal relationship from VKTX graph: y a given regulatory authority, suc…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from VKTX graph: from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therap…
ORANY	ORANY	72%	from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therapies that are in various stages of clinical development for conditions characterized…
SEPN	Septerna, Inc.	72%	Reciprocal relationship from SEPN graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from SEPN graph: result in significant additional expense and we may be subject to penalties …
TERN	Terns Pharmaceuticals, Inc.	72%	Reciprocal relationship from TERN graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from TERN graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from TERN g…
TERN	Terns Pharmaceuticals, Inc.	72%	y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products …

Viking Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
CRBP	Corbus Pharmaceuticals Holdings, Inc.	72%	Reciprocal relationship from CRBP graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from CRBP g…
IBIO	iBio, Inc.	72%	Reciprocal relationship from IBIO graph: Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Biosc…
LGND	Ligand Pharmaceuticals Incorporated	72%	from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therapies that are in various stages of clinical development for conditions characterized…
LGND	Ligand Pharmaceuticals Incorporated	72%	Reciprocal relationship from LGND graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from LGND graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from LGND g…
LGNZZ	LGNZZ	72%	Reciprocal relationship from LGNZZ graph: Reciprocal relationship from VKTX graph: from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therap…
LGNZZ	LGNZZ	72%	from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therapies that are in various stages of clinical development for conditions characterized…
MTVA	MetaVia Inc.	72%	Reciprocal relationship from MTVA graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from MTVA graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from MTVA g…
ORANY	ORANY	72%	from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therapies that are in various stages of clinical development for conditions characterized…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from VKTX graph: from non-elective hip fracture su…
CORDEN-PHARMA-COLORADO-INC	CORDEN-PHARMA-COLORADO-INC	62%	. As stock-based compensation expense recognized is based on options ultimately expected to vest, the fair value of each employee option grant during the three months ended March 31, 2026 was estimat…
HELSINN-GROUP	HELSINN-GROUP	62%	from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therapies that are in various stages of clinical development for conditions characterized…
IN-CATALYST-PHARMS-INC	IN-CATALYST-PHARMS-INC	62%	from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therapies that are in various stages of clinical development for conditions characterized…
ONE-PACIFIC-HEIGHTS-LLC	ONE-PACIFIC-HEIGHTS-LLC	62%	. As stock-based compensation expense recognized is based on options ultimately expected to vest, the fair value of each employee option grant during the three months ended March 31, 2026 was estimat…

Viking Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
VKTX-DEBT-13375	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2017-03-31.
VKTX-DEBT-13374	Warrants outstanding: 637087	90%	xbrl warrant detail from xbrl 2020-12-31.

Viking Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Viking Therapeutics, Inc..

Viking Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
VKTX-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC	VANGUARD CAPITAL MANAGEMENT LLC	90%	13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 418 tracked holders.

Viking Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
ORANY	ORANGE	100.00	1	['customer', 'supplier']
IBIO	iBio, Inc.	100.00	1	['customer', 'supplier']
BBIO	BridgeBio Pharma, Inc.	100.00	2
CRMD	CorMedix Inc.	100.00	2
ARWR	Arrowhead Pharmaceuticals, Inc.	100.00	1	['supplier']
GNMSF	Genmab A/S	100.00	2
LGNZZ	LIGAND PHARMACEUTICALS INC	100.00	1	['customer', 'supplier']
LGND	Ligand Pharmaceuticals Incorporated	100.00	1	['customer', 'supplier']
NVO	Novo Nordisk A/S	100.00	2
GYRE	Gyre Therapeutics, Inc.	100.00	1	['supplier']
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	1	['supplier']
AGEN	Agenus Inc.	100.00	2
GPCR	Structure Therapeutics Inc.	100.00	1	['supplier']
ELUT	Elutia Inc.	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	1	['customer', 'supplier']
AZN	AstraZeneca PLC	100.00	2
CLDX	Celldex Therapeutics, Inc.	100.00	2
BCYC	Bicycle Therapeutics plc	100.00	2
BHC	Bausch Health Companies Inc.	100.00	1	['supplier']
HEPA	Hepion Pharmaceuticals, Inc.	100.00	1	['supplier']

Viking Therapeutics, Inc. Supply Chain